Navigation Links
Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
Date:11/5/2013

SAN DIEGO, Nov. 5, 2013 /PRNewswire/ -- Pfenex Inc. today announced that it has awarded Paragon Bioservices a contract for the current Good Manufacturing Practice (cGMP) manufacturing of its rPA based anthrax vaccine. Paragon Bioservices will implement the cGMP-ready Pfenex Expression Technology™-based production process that has been developed at Pfenex, through its vaccines division.  Funding will be provided by the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA).

"We are pleased to award this contract to Paragon Bioservices," stated Bertrand C. Liang, Chief Executive Officer. "This is the next step in reaching our common objective with BARDA to develop an anthrax vaccine with a product capable of achieving the goals of the Strategic National Stockpile for the U. S. Government, including cost, shelf life, and administration improvements. With Paragon Bioservices we believe we will rapidly implement the large-scale cGMP production of the rPA required for our Phase 1 clinical trial."

Marco A. Chacon, Ph.D., CEO of Paragon stated, "My team and I are dedicated to providing manufacturing support to Pfenex, using their powerful protein expression technology. This project becomes all the more important since it will enrich the national armamentarium of vaccines against potential bio weapons."

About Pfenex Inc.

Pfenex Inc. is a biotechnology company developing biosimilars and innovative vaccines to address unmet and growing global healthcare needs. Utilizing the company's core technology, Pfenex Expression Technology™ for recombinant protein expression, Pfenex is able to rapidly develop and produce high quality therapeutics. In addition, Pfenex also produces and markets research proteins and reagent proteins for the research and drug development community through its Reagent Proteins division. For more information please visit www.pfenex.com  

About Paragon Bioservices Inc.

Founded in 1990, Paragon Bioservices is a contract research and manufacturing organization whose focus is the production of reagent-grade proteins and biopharmaceuticals for clinical use. Areas of expertise include: Vaccines, VLP technologies, therapeutic proteins, monoclonal antibodies and viral vectors. The cGMP manufacturing space includes microbial and mammalian suites, fill-finish, and fully-segregated Virus/BSL-3 facilities.


'/>"/>
SOURCE Pfenex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine
2. Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual Stevie® Awards for Women in Business
3. CSL Behring Awards LEAD Grant to Patient Organizations to Educate Constituents on State Insurance Exchanges
4. Sweet Success for Hosmac India Pvt. Ltd. at ET NOW-IndiaMART Leaders of Tomorrow Awards 2011
5. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
6. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
7. Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus
8. The 14th Annual LOréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrows Scientific Talents
9. UBM Canon, the Global MedTech Authority, and the Medical Design Excellence Awards Announce Dean Kamen as the Presenter of the 2012 Lifetime Achievement Award
10. Trinity College Dublins Neuroscience and Bioengineering Programmes Receive Postgraduate Course of the Year Awards
11. aTyr Pharma Receives Industry Innovation Awards from TiE and San Diego Venture Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... , Aug. 16, 2017  Kingfisher Talent, the ... development, and Virdis Group, global executive search specialists in the ... enables clients to leverage the expertise and reach of both ... here in the Boston biotech hub, ... leadership talent throughout the US, Canada ...
(Date:8/15/2017)... , ... August 15, 2017 , ... ... biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of the new ... steps needed to gain kinetic binding data for a wide range of molecules, ...
(Date:8/15/2017)... , ... August 15, 2017 , ... ... family of 6” modular downlights designed to stay tightly sealed and perform efficiently ... where damp and wet location listings just aren't enough, such as: hospitals; behavioral ...
(Date:8/15/2017)... ... 15, 2017 , ... JULABO USA introduces its new website ... makes it easy to navigate through the site whether you’re in the office, ... information, educational industry content and visit the company’s social media accounts, all on ...
Breaking Biology Technology:
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/23/2017)... 23, 2017 The report "Gesture Recognition and Touchless Sensing ... Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is expected ... 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
Breaking Biology News(10 mins):